Semagacestat, also known as LY450139 or LY-450139, is a small molecule inhibitor of gamma-secretase, an enzyme that plays a critical role in the development of Alzheimer's disease. In this article, we will delve into the chemical properties of Semagacestat, its health benefits, potential effects, mechanism of action, possible side effects, and dosing information.
The chemical name of Semagacestat is (2S)-2-hydroxy-N-((1S)-1-methyl-2-phenylethyl)-4-(methylsulfonyl)benzamide. Its molecular formula is C19H25NO4S and formula weight is 371.47 g/mol. The CAS number of Semagacestat is 425386-60-3.
Top Ten Keywords and Synonyms
Semagacestat has shown potential benefits in treating Alzheimer's disease by blocking the production of beta-amyloid protein, which forms plaques in the brain and contributes to neuronal damage. It may also have applications in other neurodegenerative disorders such as Parkinson's disease and Huntington's disease.
Semagacestat primarily acts as an inhibitor of gamma-secretase, which is involved in the cleavage of amyloid precursor protein (APP) to produce beta-amyloid protein. By blocking gamma-secretase, Semagacestat can reduce the production of beta-amyloid protein, which may slow or prevent the development of Alzheimer's disease. Additionally, it has been shown to affect the levels of tau protein, another protein that is associated with Alzheimer's disease pathology.
Gamma-secretase is an enzyme that cleaves APP to produce beta-amyloid protein, a hallmark feature of Alzheimer's disease. Semagacestat selectively inhibits gamma-secretase, thereby reducing the production of beta-amyloid protein. This ultimately reduces the formation of plaques in the brain and prevents neuronal damage.
Semagacestat has demonstrated a good safety profile in preclinical studies. However, there is limited information on its safety in humans, and further research is needed to determine its long-term safety and potential toxicities.
There is limited information on the side effects of Semagacestat in humans. In clinical trials, patients receiving Semagacestat experienced more adverse effects than those receiving placebo, including skin cancers and infections. Additionally, some patients experienced worsening cognitive function, possibly due to an off-target effect of Semagacestat on another protein called Notch.
Semagacestat has been administered orally in clinical trials at doses ranging from 50 to 140 mg once daily. The optimal dose and duration of treatment for Alzheimer's disease are unknown, and further research is needed to establish safe and effective dosing regimens.
Semagacestat is a promising inhibitor of gamma-secretase with potential therapeutic applications in Alzheimer's disease and other neurodegenerative disorders. Its mechanism of action involves reducing the production of beta-amyloid protein, which forms plaques in the brain and contributes to neuronal damage. While it has demonstrated a good safety profile in preclinical studies, more research is needed to determine its long-term safety and potential side effects in humans. Nonetheless, Semagacestat has great potential as a novel therapeutic agent in the treatment of Alzheimer's disease and other neurological disorders.